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Abstract Peptidylarginine deiminases (PADs) are a group of
enzymes which convert protein arginine residues to citrulline
residues. Using rat muscle PAD cDNA as a probe, we obtained
two novel cDNAs, PAD-R11 and PAD-R4, from immortalized
rat keratinocytes treated with all-trans retinoic acid. Comparison
of the deduced amino acid sequences with those of muscle and
hair follicle enzymes showed high conservation in the C-terminal
region. Recombinant proteins encoded by both PAD-R11 and
PAD-R4 showed the enzyme activities. That of PAD-R11
showed a characteristic feature of the enzyme found in the
epidermis.
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1. Introduction
The process of normal epidermal di¡erentiation is charac-
terized by a series of morphologic changes as keratinocytes
progress from the germinative basal layer through the spinous
and granular layers to the outer corni¢ed layer. The climax of
the process is the transition from the granular cells to the
corni¢ed cells, during which a number of proteins are sub-
jected to various post-translational modi¢cations. We recently
reported the presence of deiminated forms of keratins and
¢laggrin, which is a kind of keratin-associated protein, in
the corni¢ed layer of mammalian epidermis [1,2]. This led
us to suggest a possible role of ‘protein deimination’ during
the corni¢cation of epidermis. The ‘protein deimination’ is
catalyzed by ‘peptidylarginine deiminase’ (PAD; EC
3.5.3.15) which converts arginine residues to citrulline residues
[3^11]. There are at least three types of PADs in mammalian
tissues, i.e. ‘type I’ or ‘epidermal type’, ‘type II’ or ‘muscle
type’ and ‘type III’ or ‘hair follicle type’, all of which have a
de¢nite requirement for calcium ion. These enzymes di¡er in
their relative activities towards synthetic substrates [8], elution
pro¢les from anion exchange columns [9] or cross-reactivities
with a polyclonal antibody to PAD type II [8,9]. The complete
amino acid sequences of PAD type II and PAD type III have
been deduced from their relevant cDNA sequences [12^14].
The cDNA cloning of the remaining type I enzyme is crucially
important to explore not only its functional role but also its
regulation during the terminal stages of epidermal di¡erentia-
tion. We found that all-trans retinoic acid (RA) induced mul-
tiple PADs in a newborn rat keratinocyte cell line, one of
which was regarded as PAD type I from its chromatographic
pro¢le and relative activities towards synthetic substrates [15].
We constructed a cDNA library from the RA-treated cells as
a possible source of PAD type I cDNA clones. Initial screen-
ing was conducted using PAD type II cDNA as a hybridiza-
tion probe, and representative clones containing novel sequen-
ces were characterized by 5P-terminal extension using the 5P-
RACE method and also by the enzymatic properties of the
encoded recombinant proteins. Here we present a cDNA
clone encoding catalytically active PAD type I. Moreover,
we obtained another cDNA clone encoding a novel type of
PAD, which was tentatively termed type IV.
2. Materials and methods
2.1. Construction and cloning of the cDNA library
A newborn rat keratinocyte cell line (kindly provided by Dr. Baden,
Cutaneous Biology Research Center, Massachusetts General Hospital,
Charlestown, MA, USA) was incubated with 5 WM RA for 4 days
under the conditions described [15]. Poly(A) RNA was extracted
using a FastTrack mRNA isolation kit (Invitrogen). An oligo(dT)-
primed cDNA library was constructed in a Vgt11 vector using a com-
plete rapid cloning system (Amersham) according to the supplier’s
instruction. About 5U105 independent clones were subjected to initial
screening by plaque hybridization using a 32P-labeled 2.3 kb EcoRI
fragment of pKS-PAD [15] covering the entire length of the coding
sequence of rat PAD type II. Hybridization was performed at 42‡C in
a solution containing 5USSPE, 50% deionized formamide, 5UDen-
hardt’s solution, 1% sodium dodecyl sulfate (SDS) and 10% dextran
sulfate. Membranes were washed twice with 2USSPE containing 0.1%
SDS at room temperature and twice with 1USSPE containing 0.1%
SDS at 65‡C, successively. Positive clones were selected, plaque-puri-
¢ed, and subcloned into a pBluescript SK3 phagemid vector (Strata-
gene) for restriction mapping. Sequencing was performed by the di-
deoxynucleotide chain termination method using a Thermo Sequenase
£uorescent labelled primer cycle sequencing kit (Amersham) and an
automated DNA sequencing system (Shimadzu, model 1000L). Clones
VPAD-R11 and VPAD-R4 were chosen for further characterization.
2.2. 5P-Rapid ampli¢cation of cDNA ends (5P-RACE)
The 5P-terminal sequence was determined using a rapid ampli¢ca-
tion of cDNA ends (RACE) system (Gibco BRL) according to the
supplier’s instruction. The antisense strand synthesis was directed with
1 Wg of poly(A) RNA and primed with 5P-ACCTCGGAGAGGG-
GCCGTGTGT-3P (R11 GSP1) or 5P-GTTCATCTTGGCCTTCG-
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GCACCT-3P (R4 GSP1) for the extension of VPAD-R11 or VPAD-
R4, respectively, followed by the terminal addition of the oligo-C tail
and the sense strand synthesis. A polymerase chain reaction (PCR)
was conducted using Takara Ex Taq polymerase (Takara Biomedi-
cals) and primed with 5P-GGCCACGCGTCGACTAGTACGGGIIG-
GGIIGGGIIG-3P (AAP) and 5P-AGTCTTCTGGAATCCGGCAAA-
3P (R11 GSP2) or 5P-ACCTTGTCGTCC TCGAAGTCCATT-3P (R4
GSP2) for the ampli¢cation of PAD-R11-RA3 or PAD-R4-RA6, re-
spectively. The PCR products were cloned into a pGEM-T Easy vec-
tor (Promega) for sequencing.
2.3. Construction of plasmids for expression of recombinant proteins
A full length cDNA clone (pPAD-R11) was constructed by insert-
ing the SacII/Sse8387I fragment of pPAD-R11-RA3 into the SacII/
Sse8387I site of VPAD-R11. Another full length cDNA clone (pPAD-
R4) was constructed by inserting the SacII/NarI fragment of pPAD-
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Fig. 1. Sequencing of rat PAD-R11. A: Schematic representation of the sequencing strategy. B: Nucleotide and deduced amino acid sequences
of PAD-R11. Nucleotide and amino acid numbers are shown on the left. An asterisk denotes the position of the in-frame stop codon located
upstream of the putative initiation codon. A consensus sequence for the polyadenylation signal is underlined. The sequence data will appear in
the DDBJ/EMBL/GenBank Nucleotide Sequence Data Libraries under accession number AB010998.
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R4-RA6 into the SacII/NarI site of VPAD-R4. A region containing
the entire coding sequence of pPAD-R11 (nucleotides 131^2223) was
ampli¢ed by PCR using 5P-CCGCTCGAGATTGAATTCCATATG-
GCCTCCCAGCGAGCTGTGCA-3P (R11 exp1) containing the
underlined EcoRI site as a sense primer, and 5P-CCGGAATTC-
GCGGCCGCTCAGTCCGCTTTCAGGCTCCAGG-3P (R11 exp2)
containing the underlined NotI site as an antisense primer. In a similar
manner, a region containing the entire coding sequence of pPAD-R4
(nucleotides 17^2155) was ampli¢ed using 5P-ACGCGTCGACTC-
GAATTCCATATGGCCCAGGGTGCGGTGATC-3P (R4 exp1)
containing the underlined EcoRI site and 5P-CCGGAATTC-
GCGGCCGCAGATGTGGGTGAAGCAAAGCAAC-3P (R4 exp2)
containing the underlined NotI site as sense and antisense primers,
respectively. The ampli¢ed DNA fragments were subcloned into a
pGEX-6P vector (Pharmacia) containing a glutathione S-transferase
(GST) sequence and its nucleotide sequence was con¢rmed by DNA
sequencing. Plasmids pGEX-R11 and pGEX-R4 obtained were used
to transform JM105 cells. The transformants were grown overnight
and treated for 4 h with 0.1 mM isopropyl-1-thio-L-D-galactopyrano-
side at 20‡C. The cells were then disrupted by sonication, and the
recombinant proteins in the soluble fraction were adsorbed to Gluta-
thione Sepharose 4B (Pharmacia). PAD moieties were released using
PreScission Protease (Pharmacia) according to the supplier’s instruc-
tion. PAD activities were determined by measuring the conversion of
benzoyl-L-arginine ethyl ester (BAEE) or benzoyl-L-arginine (Bz-L-
Arg) to the corresponding derivatives of citrulline [8], and the speci¢c
activity was determined as described [15].
2.4. Northern blot hybridization
The poly(A) RNA was electrophoresed in a 0.8% agarose-form-
aldehyde gel and transferred to nylon membrane. cDNA fragments,
nucleotides 3109^3523, 2023^2227 and 2409^2837 of PAD-R11, PAD-
R4, and rat PAD type II cDNA, respectively, were ampli¢ed by PCR
using appropriate primers for the preparation of 32P-labeled probes.
Hybridization was performed under the condition used for the plaque
hybridization. The membrane was ¢nally washed at 65‡C in 1USSPE
containing 0.1% SDS. The signals were detected using a BASS 2500
image analyzer (Fuji Photo Film Co., Ltd.).
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Fig. 2. Sequencing of rat PAD-R4. A: Schematic representation of the sequencing strategy. B: Nucleotide and deduced amino acid sequences
of PAD-R4. Nucleotide and amino acid numbers are shown on the left. A consensus sequence for the polyadenylation signal is underlined.
The sequence data will appear in the DDBJ/EMBL/GenBank Nucleotide Sequence Data Libraries under accession number AB010999.
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3. Results
3.1. Cloning and sequencing of PAD cDNA clones
Nine positive clones were characterized by restriction map-
ping and partial sequencing. These clones were classi¢ed into
three groups. Representative clones of these groups bearing
the longest insert sizes were completely sequenced. They were
termed VPAD-R5 (V0.9 kbp), VPAD-R11 (V3.2 kbp), and
VPAD-R4 (V2.1 kbp). The other clones had overlapping re-
striction maps with one of these representative cDNAs.
VPAD-R5 was not used for further characterization, since it
consisted of 875 bp which exactly coincided with the 57 bp
coding sequence and the contiguous 818 bp 3P-untranslated
sequences of rat PAD type II cDNA. VPAD-R11 (3172 bp)
and VPAD-R4 (2116 bp) contained sequences encoding 516
and 512 amino acid residues, respectively, both showing sim-
ilarities to the coding sequence of rat PAD type II (Figs. 1A
and 2A, respectively). Such similarities were not found in the
adjacent 3P-untranslated sequences. Sequences missing from
the 5P-end regions of the relevant mRNAs were estimated
by the 5P-RACE method. This yielded pPAD-R11-RA3 (759
bp) for VPAD-R11 and pPAD-R4-RA6 (528 bp) for VPAD-
R4. These combinations constructed cDNA sequences PAD-
R11 (3740 bp) and PAD-R4 (2258 bp), respectively.
As Fig. 1B shows, PAD-R11 contains an open reading
frame of 1989 nucleotides encoding a polypeptide of 662 ami-
no acid residues with a calculated molecular mass of 73 856
Da. The putative initiation codon (nucleotides 131^133) is
located within a sequence context favorable for Kozak’s rule
[16], and is preceded by an in-frame stop codon (nucleotides
68^70). A putative polyadenylation signal (AATTAAA) [17] is
located at nucleotides 3717^3723. As Fig. 2B shows, PAD-R4
contains an open reading frame of 2001 nucleotides encoding
a polypeptide of 666 amino acids, with a calculated molecular
mass of 74 466 Da. The putative initiation codon (nucleotides
17^19) is located within a sequence context favorable for Ko-
zak’s rule. No in-frame stop codon is present in the estimated
sequence. A putative polyadenylation signal (AATAAA) is
located at nucleotides 2229^2234.
3.2. Comparison of sequence similarity
The amino acid sequences of PAD-R11 and PAD-R4 are
compared with those of rat PAD types II and III in Fig. 3.
About 50% of amino acid residues in the C-terminal halves
are identical, while only about 24% of amino acid residues are
common in the N-terminal halves. The entire amino acid se-
quences of PAD-R11 and PAD-R4 showed 50^57% identity
with that of rat PAD type II or type III when compared in
pairs. The corresponding nucleotide sequences showed a
somewhat higher identity (61^65%).
3.3. PAD activities of recombinant proteins
To construct GST expression plasmids, the coding regions
of PAD-R11 and PAD-R4 were ampli¢ed and inserted into
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Fig. 3. Sequence comparison of PAD-R11 and PAD-R4 with rat PAD type II and type III. Alignment of putative amino acid sequences of
PAD-R11 and PAD-R4 with rat PAD type II and type III. Amino acids conserved in all proteins are shadowed. Dashes indicate gaps inserted
to maximize alignment.
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the pGEX-6P vector. The PAD moieties of these recombinant
proteins in bacteria were obtained by the a⁄nity adsorption
followed by the PreScission Protease cleavage. This resulted in
about 50-fold puri¢cation of the recombinant protein encoded
by PAD-R11 from the crude extract. The recombinant protein
encoded by PAD-R4 was puri¢ed several-fold. The former
showed speci¢c activities of 2.1 to BAEE and 2.4 to Bz-L-
Arg, in terms of units of the enzyme activity per mg protein.
Those the latter were 6.3 and 1.1, respectively. No enzyme
activities were detected in the extract of the bacteria trans-
formed with the control pGEX-6P vector.
3.4. Analysis of mRNA expression
We performed Northern blot hybridization of poly(A)
RNA fractions to see if relevant mRNAs are speci¢cally ex-
pressed in RA-treated cells (Fig. 4). Appropriate regions in
the 3P-untranslated sequences were selected for probing to
minimize cross-hybridization. The selected probes represent-
ing rat PAD type II cDNA, PAD-R11, and PAD-R4 yielded a
single band of transcriptV4.5 kbp,V3.8 kbp andV2.3 kbp,
respectively. No signi¢cant hybridization signals were detected
with the poly(A) RNA fraction obtained from untreated
cells.
4. Discussion
Our principal aim was to obtain a cDNA clone encoding
catalytically active PAD type I. We chose RA-treated immor-
talized rat keratinocytes as the source of cDNA, which were
found to synthesize multiple PADs including PAD type I and
type II [15]. We obtained three di¡erent groups of PAD
cDNA clones based on the homology to rat PAD type II
cDNA. One group of cDNA clones represented by VPAD-
R5 appeared to be derived from PAD type II mRNA itself.
Sequencing of the representative clones and 5P-terminal exten-
sion using the 5P-RACE method enabled us to construct two
cDNA sequences, PAD-R11 and PAD-R4, that have not been
reported previously. To distinguish which cDNA encodes
PAD type I, we constructed bacterially expressed recombinant
proteins to measure their relative activities towards the syn-
thetic substrates. The puri¢ed recombinant protein encoded
by PAD-R11 showed nearly equal activities towards BAEE
and Bz-L-Arg. Since this is a unique feature of PAD type I
among the three known types of PAD [8,9], PAD-R11 was
identi¢ed to encode PAD type I. The puri¢ed recombinant
protein encoded by PAD-R4 showed a higher activity towards
BAEE than to Bz-L-Arg, resembling PAD types II and III.
We tentatively call it type IV PAD cDNA. These three di¡er-
ent PAD mRNAs were con¢rmed to be expressed in RA-
treated cells but not in untreated cells by Northern blot anal-
yses. Since RA is known to negatively modulate various ter-
minal di¡erentiation processes such as synthesis and process-
ing of pro¢laggrin [18], and expression of keratins [19] and
loricrin [20,21], it is not certain if PAD types II and IV are
expressed in animal epidermis. Such questions should be an-
swered by immunocytochemical approaches using speci¢c
antibodies and/or in situ hybridization analyses using relevant
cDNA sequences.
Deiminated forms of keratins and ¢laggrin in the corni¢ed
layer were found as the reaction products of PAD type I in
our previously studies [1,2]. Trichohyalin was shown to be the
natural substrate for PAD type III and found in highly de-
iminated forms in the mature hardened layers of the inner
root sheath of hair follicles and the medulla of hair [22,23].
Recently, we reported that vimentin was preferentially deimi-
nated in mouse peritoneal macrophages undergoing calcium
ionophore-induced apoptosis, although the PAD type in-
volved was not identi¢ed precisely [24]. These data suggest
that PADs may act on intermediate ¢lament proteins and/or
intermediate ¢lament-associated proteins in cells undergoing
degenerative processes. The relatively high sequence conserva-
tion in the C-terminal region suggests its possible involvement
in the common functions such as the catalytic activity and the
calcium binding activity. The N-terminal region might be in-
volved in the selective recognition of target proteins in rele-
vant tissues. The availability of multiple types of PAD cDNA
sequences will open a fascinating avenue by which to explore
the regulation of their expression, as well as the molecular
characterization of PADs themselves.
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